rifaximin + propranolol

A combination therapy consisting of rifaximin (a non-systemic, gastrointestinal site-specific antibiotic) and propranolol (a non-selective beta blocker). This combination has shown an additive effect in improving portal hypertension compared to propranolol monotherapy in patients with cirrhosis. The mechanism involves both the reduction of bacterial translocation by rifaximin and the hemodynamic effects of propranolol on portal pressure. ## Mechanism and Effectiveness Rifaximin is a non-systemic, gastrointestinal site-specific antibiotic that works by inhibiting bacterial RNA synthesis in susceptible bacteria. It helps reduce bacterial translocation (BT), which is an aggravating factor in portal hypertension among cirrhosis patients[1][6]. Propranolol is a non-selective beta-blocker (NSBB) that has been the standard treatment for preventing portal hypertension-related complications. However, its effectiveness as a monotherapy is often limited[1][6]. When combined, these medications show an additive effect in improving portal hypertension. Clinical studies have demonstrated that the combination therapy results in: - Higher HVPG response rates compared to propranolol monotherapy (87.5% vs 56.2%)[1][6] - Greater reduction in HVPG values[6] - Significant decreases in bacterial translocation-related markers (LPS, LBP, IL-6, TNF-α)[1] ## Clinical Evidence A randomized controlled pilot study showed that after treatment, portal pressure declined significantly in both monotherapy and combination therapy groups, but the HVPG response rate was significantly greater in the combination therapy group[6]. The HVPG change rate was also significantly greater in the combination therapy group than in the monotherapy group (34.75%±24.21% vs 18.93%±22.90%)[6]. This combination therapy appears to be a promising approach for overcoming the limited effectiveness of NSBBs alone in managing portal hypertension in cirrhosis patients.

Other names

Rifaximin and propranolol combination therapy